Analytical and clinical evaluation of two homogeneous assays for LDL-cholesterol in hyperlipidemic patients

58Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: LDL-cholesterol (LDL-C) concentrations are the primary basis for treatment guidelines established for hyperlipidemic patients. LDL-C concentrations are commonly monitored by means of the Friedewald formula, which provides a relative estimation of LDL-C concentration when the triglyceride concentration is <2000 mg/L and there are no abnormal lipids. The Friedewald formula has several limitations and may not meet the current total error requirement of <12% in LDL-C measurements. Methods: We evaluated the analytical and clinical performance of two direct methods (Roche and Wako) by analyzing 313 fresh serum samples obtained from dyslipidemic patients in a lipid clinic and comparing them with modified β-quantification. Results: Both homogeneous assays displayed excellent precision (CV <2%). The Roche method showed a mean total error of 7.72%, and the Wako method showed a mean total error of 4.46% over a wide range of LDL-C concentrations. The Roche method correlated highly with the modified β-quantification assay (r = 0.929; y = 1.052x - 168 mg/L; n = 166) and showed a bias of -4.5% as a result of the assigned standard value. The Wako method also correlated highly with β-quantification (r = 0.966; y = 0.9125x + 104.8 mg/L; n = 145) without significant bias. The Roche method correctly classified 97% of patients with triglycerides <2000 mg/L, 75% of patients with type IIb hyperlipemia (HPL), and 84% of patients with type IV HPL based on the cutpoints of 1300 and 1600 mg/L, compared with 98%, 78.4%, and 89%, respectively, for the Wako method. In dysbetalipoproteinemic patients, both methods have a 30% mean positive bias compared with β-quantification. Conclusions: Both direct methods can be a useful alternative when ultracentrifugation is not available for the diagnosis and control of lipid-lowering medication for patients with mixed HPL, but not for patients with type III hyperlipidemia. (C) 2000 American Association for Clinical Chemistry.

Cite

CITATION STYLE

APA

Esteban-Salan, M., Guimon-Bardesi, A., De La Viuda-Unzueta, J. M., Azcarate-Ania, M. N., Pascual-Usandizaga, P., & Amoroto-Del-Rio, E. (2000). Analytical and clinical evaluation of two homogeneous assays for LDL-cholesterol in hyperlipidemic patients. Clinical Chemistry, 46(8 I), 1121–1131. https://doi.org/10.1093/clinchem/46.8.1121

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free